diaDexus lands $9.2M for cardiovascular diagnostics

February 11, 2009 | Camille Ricketts | Comments | |
South San Francisco, Calif. biotech firm diaDexus just raised $9.2 million in sixth-round funding from Scale Venture Partners, GlaxoSithKline and Baker Brothers Advisors, according to peHUB. The company’s first and only product, the PLAC Test, is used to detect early indicators of risk for heart attack and stroke. If such conditions can be determined at an early stage, aggressive treatment can prevent possibly-fatal events from ever occurring, diaDexus claims.
Founded in 2000, the company had raised $170 million in capital previous to the recent round. This money came from Burrill & Co., Rho Ventures, Bain Capital’s Brookside Fund and Mosaix Ventures. It last raised funds at the beginning of 2007 amounting to $40 million.

Next Story: Golden Gateway scores $5 million for reverse mortgages
Previous Story: Online pet supply catalog FetchDog vies for dog enthusiast dollars

Bookmark and Share

Tags: , , , , , ,

Photo of Camille Ricketts

About the Author, Camille Ricketts

Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.

With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.